FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 08:48:11 2024-06-20 EDT | ||
| 51.86 EUR / 52.97 EUR | +1.19% |
|
| Current month | +17.54% | ||
| 1 month | +13.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 52.19 | +0.75% |
| 24-06-19 | 51.8 | -5.46% |
| 24-06-18 | 54.79 | -2.20% |
| 24-06-17 | 56.02 | +1.36% |
| 24-06-14 | 55.27 | +2.28% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 06:43 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD0HTL |
| ISIN | DE000MD0HTL2 |
| Date issued | 2021-12-13 |
| Strike | 311.6 $ |
| Maturity | Unlimited |
| Parity | 2.78 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58.39 € |
|---|---|
| Lowest since issue | 9.81 € |
| Spread | 1.11 € |
| Spread % | 2.10% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat
